114 related articles for article (PubMed ID: 7550016)
1. Pharmacokinetics and biodistribution of radiolabelled idoxifene: prospects for the use of PET in the evaluation of a novel antioestrogen for cancer therapy.
Young H; Carnochan P; Trivedi M; Potter GA; Eccles SA; Haynes BP; Jarman M; Ott RJ
Nucl Med Biol; 1995 May; 22(4):405-11. PubMed ID: 7550016
[TBL] [Abstract][Full Text] [Related]
2. Biodistribution and kinetics of radiolabelled pyrrolidino-4-iodo-tamoxifen: prospects for pharmacokinetic studies using PET.
Carnochan P; Trivedi M; Young H; Eccles S; Potter G; Haynes B; Ott R
J Nucl Biol Med (1991); 1994 Dec; 38(4 Suppl 1):96-8. PubMed ID: 7632777
[TBL] [Abstract][Full Text] [Related]
3. Imaging, biodistribution and therapy potential of halogenated tamoxifen analogues.
Yang DJ; Li C; Kuang LR; Price JE; Buzdar AU; Tansey W; Cherif A; Gretzer M; Kim EE; Wallace S
Life Sci; 1994; 55(1):53-67. PubMed ID: 8015349
[TBL] [Abstract][Full Text] [Related]
4. Tissue distribution of the radiolabeled antiestrogen [125I]iodotamoxifen.
Hanson RN; Seitz DE
Int J Nucl Med Biol; 1982; 9(2):105-7. PubMed ID: 7107123
[No Abstract] [Full Text] [Related]
5. Biodistribution of 123I-labeled 4-hydroxytamoxifen derivatives in rats with dimethylbenzanthracene-induced mammary carcinomas.
Kruijer PS; Klok RP; van den Koedijk CD; Blankenstein MA; Voskuil JH; Verzeijlbergen JF; Ensing GJ; Herscheid JD
Nucl Med Biol; 1997 Nov; 24(8):719-22. PubMed ID: 9428596
[TBL] [Abstract][Full Text] [Related]
6. Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats.
Nuttall ME; Bradbeer JN; Stroup GB; Nadeau DP; Hoffman SJ; Zhao H; Rehm S; Gowen M
Endocrinology; 1998 Dec; 139(12):5224-34. PubMed ID: 9832463
[TBL] [Abstract][Full Text] [Related]
7. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
[TBL] [Abstract][Full Text] [Related]
8. Idoxifene is equipotent to tamoxifen in inhibiting mammary carcinogenesis but forms lower levels of hepatic DNA adducts.
Pace P; Jarman M; Phillips D; Hewer A; Bliss J; Coombes RC
Br J Cancer; 1997; 76(6):700-4. PubMed ID: 9310233
[TBL] [Abstract][Full Text] [Related]
9. Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer.
Chander SK; McCague R; Luqmani Y; Newton C; Dowsett M; Jarman M; Coombes RC
Cancer Res; 1991 Nov; 51(21):5851-8. PubMed ID: 1933854
[TBL] [Abstract][Full Text] [Related]
10. Radiolabelled 5'-iodo-2'-deoxyuridine: a promising alternative to [18F]-2-fluoro-2-deoxy-D-glucose for PET studies of early response to anticancer treatment.
Carnochan P; Brooks R
Nucl Med Biol; 1999 Aug; 26(6):667-72. PubMed ID: 10587105
[TBL] [Abstract][Full Text] [Related]
11. Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines.
Sharp SY; Rowlands MG; Jarman M; Kelland LR
Br J Cancer; 1994 Sep; 70(3):409-14. PubMed ID: 8080723
[TBL] [Abstract][Full Text] [Related]
12. Comparative antioestrogen action in experimental breast cancer.
Jordan VC
Adv Exp Med Biol; 1981; 138():165-78. PubMed ID: 6805259
[No Abstract] [Full Text] [Related]
13. Amino and iodotamoxifens: synthesis, estrogen receptor affinity and biodistribution.
Strickland LA; Ponce YZ; Hunter DH; Zabel PL; Powe JE; Morrissey G; Driedger AA; Chamberlain MJ; Tustanoff ER
Drug Des Deliv; 1990 Sep; 6(3):195-212. PubMed ID: 1963782
[TBL] [Abstract][Full Text] [Related]
14. Homologs of idoxifene: variation of estrogen receptor binding and calmodulin antagonism with chain length.
Hardcastle IR; Rowlands MG; Grimshaw RM; Houghton J; Jarman M
J Med Chem; 1996 Feb; 39(4):999-1004. PubMed ID: 8632423
[TBL] [Abstract][Full Text] [Related]
15. Idoxifene and estradiol enhance antiapoptotic activity through estrogen receptor-beta in cultured rat hepatocytes.
Inoue H; Shimizu I; Lu G; Itonaga M; Cui X; Okamura Y; Shono M; Honda H; Inoue S; Muramatsu M; Ito S
Dig Dis Sci; 2003 Mar; 48(3):570-80. PubMed ID: 12757172
[TBL] [Abstract][Full Text] [Related]
16. The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance.
Johnston SR; Riddler S; Haynes BP; A'Hern R; Smith IE; Jarman M; Dowsett M
Br J Cancer; 1997; 75(6):804-9. PubMed ID: 9062399
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of [18F]fluoroalanine and [18F]fluorotamoxifen for imaging breast tumors.
Yang D; Kuang LR; Cherif A; Tansey W; Li C; Lin WJ; Liu CW; Kim EE; Wallace S
J Drug Target; 1993; 1(3):259-67. PubMed ID: 8069568
[TBL] [Abstract][Full Text] [Related]
18. Idoxifene: report of a phase I study in patients with metastatic breast cancer.
Coombes RC; Haynes BP; Dowsett M; Quigley M; English J; Judson IR; Griggs LJ; Potter GA; McCague R; Jarman M
Cancer Res; 1995 Mar; 55(5):1070-4. PubMed ID: 7866990
[TBL] [Abstract][Full Text] [Related]
19. Biodistribution and scintigraphy of 11C-toremifene in rats bearing DMBA-induced mammary carcinoma.
Kangas L; Haaparanta M; Paul R; Roeda D; Sipilä H
Pharmacol Toxicol; 1989 Apr; 64(4):373-7. PubMed ID: 2526330
[TBL] [Abstract][Full Text] [Related]
20. Activity of the antioestrogen trioxifene against N-Nitrosomethylurea-induced rat mammary carcinomas.
Rose DP; Fischer AH; Jordan VC
Eur J Cancer Clin Oncol; 1981 Aug; 17(8):893-8. PubMed ID: 7198978
[No Abstract] [Full Text] [Related]
[Next] [New Search]
